Canaccord downgraded Bioceres (BIOX) to Hold from Buy with a price target of $2.50, down from $6.50. The company’s sales and adjusted EBITDA loss in fiscal Q4 were lower than expected due to macro challenges being faced by agriculture customers in in its core market of Argentina, the analyst tells investors in a research note. The firm cites the challenging market in Argentina and the overhang of Bioceres’ parent company reducing its position for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres Crop Solutions Faces Challenging Fiscal Year
- Bioceres Crop Solutions Earnings Call Highlights Challenges and Recovery
- Bioceres Crop Solutions Faces Challenging FY25 Amid Argentine Market Pressures
- Bioceres reports Q4 revenue $74.7M, consensus $110.08M
- BIOX Upcoming Earnings Report: What to Expect?